FDA panel rejects psychedelic-assisted therapy for PTSD

Members of the group pointed to flawed study data and significant drug risks: US.
HealthDay News

A US Food and Drug Administration advisory panel has voted against recommending the psychedelic MDMA for the treatment of PTSD.

In a 10-1 vote, the panel determined the evidence amassed so far fails to show the controversial drug’s benefits outweigh its risks, the Associated Press (AP) reported.